Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 20;7:1097. doi: 10.1038/s41598-017-00957-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Anti-cancer effects of CA IX-TPL-Lips in mice with orthotopic lung tumors. (a) Treatment schedule of TPL formulations in orthotopic A549-Luc tumor-bearing BALB/c nude mice; (b) Representative serial images of bioluminescence change in mice during treatment with different formulations of TPL including CA IX-TPL-Lips, non-targeted TPL-Lips, free TPL solution and saline as a control (n = 5) using the IVIS® Lumina XR system. (c) Survival curve of mice with orthotopic lung tumors following administration of TPL formulations. *p < 0.05, compared with saline; (d) Histological staining of organs following pulmonary administration of TPL formulations. Scale bars, 100 μm.